Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II irofulven plus prednisolone in DRP-selected metastatic castration-resistant prostate cancer after AR-targeted therapy and docetaxel
2017-003549-72Phase 2Completed
- Sponsor
- Allarity Therapeutics
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irofulven in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Allarity Therapeutics. Primary endpoint: Clinical benefit rate. Started Oct 2017; status: completed.
02
Drugs
irofulven
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2017-003549-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003549-72.